Newstral
Article
Financial Times on 2023-05-17 21:10
Mergers & Acquisitions: M&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warns
Related news
- Mergers & Acquisitions: Pharma and biotech seek cure for industry deal slumpFinancial Times
- Mergers & Acquisitions: Interview. EU to tighten rules for airline mergersFinancial Times
- TNow trending in America: mergers and acquisitionsthetriangle.org
- 5 top years for mergers and acquisitionsreviewtimes.com
- Mergers & Acquisitions: Merck buys Prometheus Biosciences for almost $11bnFinancial Times
- Mergers & Acquisitions: Due Diligence. Five big finance questions for 2023Financial Times
- Mergers and acquisitions: When tech-sector takeovers make senseThe Jerusalem Post (JPost.com)
- Mergers and acquisitions are rising, leaving crypto assessments in questioncointelegraph.com
- Mergers + Acquisitions: 5 Tips For Navigating FCPA Risksjdsupra.com
- BBig Pharma Will Turn to Mergers After Crisis, Says RBCbarrons.com
- Mergers & Acquisitions: Sharp fall in global dealmaking brings pandemic-era frenzy to a haltFinancial Times
- Mergers & Acquisitions: Dealmaking languishes at decade low on private equity droughtFinancial Times
- Mergers & Acquisitions: Raine bags $65mn fee advising WWE on Endeavor takeoverFinancial Times
- Mergers & Acquisitions: Permian Resources to acquire Earthstone Energy in $4.5bn dealFinancial Times
- Mergers & Acquisitions: Dealmakers tackle rising rates with pitch to buyers: don’t touch the debtFinancial Times
- Mergers & Acquisitions: Mizuho agrees $550mn deal for boutique investment bank GreenhillFinancial Times
- Mergers & Acquisitions: New US antitrust guidance puts private equity and tech deals in focusFinancial Times
- Mergers & Acquisitions: Viessmann’s sale of heat pump unit attracts scrutiny in BerlinFinancial Times